Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer

Cancer Investigation

Volumn 27, Issue 3, 2009, Pages 273-285

  Zhang, Yan Jie ^a,b   Tian, Xiao Qing ^a   Sun, Dan Feng ^a   Zhao, Shu Liang ^a   Xiong, Hua ^a   Fang, Jing Yuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Colorectal cancer; MEK; Prevention; Rapamycin; Signal transduction

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; RAPAMYCIN; FLAVONOID; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INCIDENCE; MONOTHERAPY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR VOLUME; ANIMAL; CELL CYCLE; COLORECTAL TUMOR; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; INSTITUTE FOR CANCER RESEARCH MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; FLAVONOIDS; HUMANS; MICE; MICE, INBRED ICR; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROTEIN KINASES; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 63349097231     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802314893     Document Type: Article

References (29)

1. Leary, A.; Johnston, S.R. Small molecule signal transduction inhibitors for the treatment of solid tumors. Cancer Invest 2007, 25(5), 347-365.
2. Wullschleger, S.; Loewith, R.; Hall, M.N. TOR signaling in growth and metabolism. Cell 2006, 124, 471-484.
3. Easton, J.B.; Houghton, P.J. mTOR and cancer therapy. Oncogene 2006, 25, 6436-6446.
4. Mamane, Y.; Petroulakis, E.; LeBacquer, O.; Sonenberg, N. mTOR, translation initiation, and cancer. Oncogene 2006, 25, 6416-6422.
5. Rubio-Viqueira, B.; Hidalgo, M. Targeting mTOR for cancer treatment. Curr Opin Invest Drugs 2006, 7, 501-512.
6. Tsang, C.K.; Qi, H.; Liu, L.F.; Zheng, X.F. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 2007, 12, 112-124. (Pubitemid 46176669)
7. Georgakis, G.V.; Younes, A. From Rapa Nui to rapamycin: targeting PI3K/Akt/mTORfor cancer therapy. Exp Rev Anticancer Ther 2006, 6, 131-140.
8. Nozawa, H.; Watanabe, T.; Nagawa, H. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer. Cancer Lett 2007, 251, 105-113. (Pubitemid 46589769)
9. Roberts, P.J.; Der, C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26, 3291-3310. (Pubitemid 46763022)
10. Fang, J.Y.; Richardson, B.C. The extracellular signal regulated kinase-mitogen -activated protein kinases signaling pathway and human colorectal cancer. Lancet Oncol 2005, 6, 322-327.
11. Lu, R.; Wang, X.; Chen, Z.F.; Sun, D.F.; Tian, X.Q.; Fang, J.Y. Inhibition of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway decrease DNA methylation in colon cancer cells. J Biol Chem 2007, 282, 12249-12259. (Pubitemid 47100721)
12. Legrier, M.E.; Yang, C.P.; Yan, H.G.; Lopez-Barcons, L.; Keller, S.M.; Pérez-Soler, R.; Horwitz, S.B.; McDaid, H.M. Targeting protein translation in human non-small-cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res 2007, 67(23), 11300-11308. (Pubitemid 350248556)
13. Faivre, S.; Djelloul, S.; Raymond, E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 2006, 33, 407-420. (Pubitemid 44142738)
14. Espina, V.; Geho, D.; Mehta, A.I.; Petricoin, E.F., 3rd; Liotta, L.A.; Rosenblatt, K.P. Pathology of the future: molecular profiling for targeted therapy. Cancer Invest 2005, 23(1), 36-46.
15. Wang, L.H.; Chan, J.L.; Li, W. Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 overexpressing breast cancer cells. Int J Cancer 2007, 121, 2911-2918. (Pubitemid 46753864)
16. Smalley, K.S.; Haass, N.K.; Brafford, P.A.; Lioni, M.; Flaherty, K.T.; Herlyn, M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006, 5, 1136-1144. (Pubitemid 43881305)
17. Lasithiotakis, K.G.; Sinnberg, T.W.; Schittek, B.; Flaherty, K.T.; Kulms, D.; Maczey, E.; et al. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol 2008 Mar 6 J Invest Dermato 2008, 128(8), 2013-2023.
18. Kilic, U.; Kilic, E.; Järve, A.; Guo, Z.; Spudich, A.; Bieber, K.; et al. Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. J Neurosci 2006, 26(48), 12439-12446.
19. Nathan, C.O.; Amirghahari, N.; Rong, X.; Giordano, T.; Sibley, D.; Nordberg, M.; et al. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res 2007, 67(5), 2160-2168.
20. Granville, C.A.; Warfel, N.; Tsurutani, J.; Hollander, M.C.; Robertson, M.; Fox, S.D.; et al. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin Cancer Res 2007, 13(7), 2281-2289.
21. Hamilton, S.R.; Vogelstein, B.; Kudo, S.; Riboli, E.; Nakamura, S.; Hainaut, P.; et al. Tumours of the colon and rectum. In: Hamilton, S.R.; Aaltonen, L. (Eds.). Pathology and Genetics of Tumours of the Digestive System. World Health Organization Classification of Tumours (pp 104-119). Lyon, France: IARC Press, 2001.
22. Hay, N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005, 8, 179-183. (Pubitemid 41317589)
23. Averous, J.; Proud, C.G. When translation meets transformation: the mTOR story. Oncogene 2006, 25, 6423-6435.
24. Dancey, J.E. Therapeutic targets: MTOR and related pathways. Cancer Biol Ther 2006, 5, 1065-1073.
25. Moon, D.O.; Park, C.; Heo, M.S.; Park, Y.M.; Choi, Y.H.; Kim, G.Y. PD98059 triggers G1 arrest and apoptosis in human leukemic U937 cells through downregulation of Akt signal pathway. Int Immunopharmacol 2007, 7, 36-45.
26. Fang, P.; Hwa, V.; Rosenfeld, R.G. Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway. Exp Cell Res 2006, 312, 1229-1239.
27. Fukazawa, H.; Noguchi, K.; Murakami, Y.; Uehara, Y. Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway. Mol Cancer Ther 2002, 1, 303-309.
28. Kumar, N.; Afeyan, R.; Kim, H.D.; Lauffenburger, D.A. Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of HER2-overexpressing mammary epithelial cells. Mol Pharmacol 2008, 73(6), 1668-1678.
29. Miller-Jensen, K.E.; Janes, K.A.; Brugge, J.S.; Lauffenburger, D.A. Common effector-processing mediates cell-specific responses to stimuli. Nature 2007, 448, 604-608.